(NASDAQ: TCRX) Tscan Therapeutics's forecast annual revenue growth rate of 151.52% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Tscan Therapeutics's revenue in 2025 is $6,961,000.On average, 3 Wall Street analysts forecast TCRX's revenue for 2025 to be $671,499,001, with the lowest TCRX revenue forecast at $581,666,928, and the highest TCRX revenue forecast at $851,219,895. On average, 3 Wall Street analysts forecast TCRX's revenue for 2026 to be $802,586,865, with the lowest TCRX revenue forecast at $141,869,983, and the highest TCRX revenue forecast at $1,372,166,471.
In 2027, TCRX is forecast to generate $7,891,035,419 in revenue, with the lowest revenue forecast at $3,783,956,173 and the highest revenue forecast at $11,998,114,664.